Here are the 10-K annual reports from Quest Diagnostics Inc. (DGX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow DGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DGX filings page.
Quest Diagnostics describes how it generates growth and improves efficiency across its global diagnostics business. The company generated net revenues of $11.0 billion in 2025 and now serves roughly half of U.S. adults over three years, with strong physician and hospital penetration.
Advanced Diagnostics™ tests in oncology, cardiometabolic and other specialties produced over $1 billion of revenue with double-digit growth, underscoring a shift toward higher‑value testing. Quest expanded through acquisitions such as LifeLabs in Canada and Spectra Laboratories assets, and a 51%/49% joint venture with Corewell Health in Michigan.
Management highlights ongoing cost and quality programs, including the Invigorate savings initiative, a multi‑year Project Nova overhaul of order‑to‑cash systems, and broader use of automation and AI, including a 2025 collaboration with Google Cloud. The company also raised its quarterly dividend about 7.5% to $0.86 per share and reports a workforce of nearly 57,000 employees.